Rafferty Asset Management
OCUL icon

Rafferty Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Rafferty Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
22,727
+7,284
+47% +$66K ﹤0.01% 1077
2026
Q1 		$131K Buy
15,443
+271
+2% +$2.58K ﹤0.01% 1045
2025
Q4 		$184K Sell
15,172
-1,399
-8% -$17K ﹤0.01% 1115
2025
Q3 		$194K Buy
16,571
+3,158
+24% +$37.8K ﹤0.01% 1078
2025
Q2 		$124K Buy
13,413
+2,343
+21% +$18.3K ﹤0.01% 1064
2025
Q1 		$81.1K Sell
11,070
-4,152
-27% -$31.9K ﹤0.01% 1050
2024
Q4 		$130K Sell
15,222
-3,209
-17% -$31.3K ﹤0.01% 1117
2024
Q3 		$160K Sell
18,431
-17,289
-48% -$143K ﹤0.01% 1117
2024
Q2 		$244K Buy
+35,720
New +$220K ﹤0.01% 1093
2023
Q4 		– Sell
-11,837
Closed -$37.2K – 1091
2023
Q3 		$37.2K Buy
+11,837
New +$48.4K ﹤0.01% 1070
2022
Q1 		– Sell
-20,022
Closed -$140K – 1296
2021
Q4 		$140K Buy
20,022
+3,988
+25% +$31K ﹤0.01% 1243
2021
Q3 		$160K Buy
16,034
+3,171
+25% +$35.6K ﹤0.01% 1200
2021
Q2 		$182K Buy
+12,863
New +$196K ﹤0.01% 1237

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's OCUL Position: Q2 2026 in Review

Rafferty Asset Management increased its Ocular Therapeutix (OCUL) stake by 47% in Q2 2026, buying an estimated $66K and bringing the position to 22,727 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #1077.

Rafferty Asset Management first reported a position in OCUL in Q2 2021 and has held it in 13 quarters since. The position peaked at $244K in Q2 2024. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Rafferty Asset Management held 22,727 shares of Ocular Therapeutix worth $223K as of Q2 2026.
  • Rafferty Asset Management bought 7,284 Ocular Therapeutix shares in Q2 2026, an estimated $66K.
  • Ocular Therapeutix made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1077 holding.
  • Rafferty Asset Management first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 13 quarters since.
  • Rafferty Asset Management's Ocular Therapeutix position peaked at $244K in Q2 2024.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.